RiverVest

@RiverVest

RiverVest Venture Partners® is a venture capital firm focused on identifying & shaping early-stage life science cos. to create significant shareholder value.

Saint Louis, MO
Vrijeme pridruživanja: veljača 2012.

Tweetovi

Blokirali ste korisnika/cu @RiverVest

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @RiverVest

  1. prije 9 sati
    Poništi
  2. proslijedio/la je Tweet
    4. velj

    Excited to announce our $25 million Series D raise, preparing us for commercial launch in June.

    Poništi
  3. 1. velj

    Beautiful story about our Managing Director Derek Rapp and his family’s enormous commitment to ⁦⁩ : Where Are They Now? Derek and Emily Rapp Seek to Grow Support for JDRF

    Poništi
  4. proslijedio/la je Tweet
    21. sij

    We are hiring! Career opportunities in in St. Louis.

    Poništi
  5. proslijedio/la je Tweet
    16. sij

    Is your fundraising? As the team wraps up at one of our entrepreneurs in residence and a bioscience , of , shares her top 5 takeaways for hoping to raise capital:

    Poništi
  6. 8. sij

    Congratulations to RiverVest Managing Director for being named one of the most influential business leaders in San Diego!

    Poništi
  7. 8. sij

    Congratulations to Ciara Kennedy, CEO of RiverVest portfolio company Amplyx, for being named one of the most influential business leaders in San Diego!

    Poništi
  8. 3. sij

    RiverVest co-founder Tom Melzer shares insights on venture capital and startup growth for 2020 in today's

    Poništi
  9. 16. pro 2019.

    RiverVest portfolio company completed a successful pre-new drug application meeting with the FDA for Maralixibat, a drug to treat pruritus associated with Alagille syndrome.

    Poništi
  10. 14. pro 2019.

    Looking forward to the Medtech Partnering Conference 2020 where Jay Schmelter, RiverVest managing director, is scheduled to speak.

    Poništi
  11. 18. stu 2019.

    RiverVest portoflio co. Wugen targets 2020 for Series A funding, start of clinical trials. RiverVest managing director John McKearn is president & CEO.

    Poništi
  12. 28. lis 2019.

    FDA granted 'Breakthrough Therapy Designation' to Maralixibat, RiverVest portfolio co. 's oral drug to treat pruritus from . Designation was based on Phase 2b clinical trial shared at Internat'l Liver Congress.

    Poništi
  13. 30. ruj 2019.

    Congrats to our portfolio co. InterVene Medical for winning 1st place (and $200k) at the Shark Tank out of 50 global clinical stage companies in cardiac, vascular and neuro!

    Poništi
  14. 20. ruj 2019.

    RiverVest portfolio company Spruce Biosciences, a clinical stage biotech co., announced positive 2a study results from Spruce's oral, non-steroid treatment of CAH, a rare genetic disorder affecting the ability of the adrenal glands to function properly.

    Poništi
  15. 13. ruj 2019.

    Gene therapy is back in business thanks to pioneer James Wilson, and we’re thrilled to have co-led the $20 million Series B round for his RiverVest’s serves on the ScoutBio board.

    Poništi
  16. proslijedio/la je Tweet
    13. kol 2019.

    Huge win for the region and for our region’s long-term civic focus to invest and grow our strength.

    Poništi
  17. proslijedio/la je Tweet
    23. srp 2019.
    Poništi
  18. 23. srp 2019.

    RiverVest continues team expansion with new managing director, Derek Rapp, and senior associate, Isaac Zike, PhD.

    Poništi
  19. 18. srp 2019.

    RiverVest portfolio company Mirum Pharmaceuticals announces pricing of IPO.

    Poništi
  20. 18. srp 2019.

    WUGEN, a RiverVest Venture Partners seed investment, is targeting T-cell cancers using CAR-T Therapy.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·